Ipamorelin
200–300 mcg · Daily or EOD
Evidence
- Human Studies
- 8
- Animal Studies
- 20
- Clinical Status
- Research
- Confidence
- Low
- Long-Term Safety
- Limited — early-phase pharmaceutical trials only; the development program was not carried to approval
What this score is: a measure of how much research exists and how far along it is (animal-only vs. human trials, research-stage vs. FDA approved) — not how safe, effective, or worth trying a compound is. A low score usually means “early stage” or “understudied,” not “bad.” A high score doesn’t mean “better” for your goals than a lower-scored one.
This is not my personal rating of the compound, not a recommendation, and not medical advice. It’s a general research synthesis for informational purposes only, not a live literature count. See the linked research and talk to a licensed clinician before making decisions based on it.
Mechanism
A selective ghrelin-receptor agonist (growth hormone-releasing peptide) that stimulates GH release with comparatively little effect on cortisol or prolactin versus older GHRPs. Some published human pharmacology data exists from its original pharmaceutical development, which was not carried through to approval.
Common Protocols
- 200–300 mcg daily or every other day, subcutaneous, often stacked with CJC-1295
Side Effects
- Injection site reaction
- Increased appetite
- Water retention
Interactions
- Combining with other GH secretagogues compounds both effect and risk
Practical Details
- Cost
- $
- Typical Vial Size
- 5 mg
- Storage
- Refrigerate after reconstitution
Research Links
Selective GH secretagogue; minimal cortisol/prolactin